Chronic Kidney Disease
A 10-year old African-American girl has progressive kidney failure from biopsyproven FSGS. Her current serum creatinine is 3.7 mg/dl and estimated GFR is 16 ml/min/1.73m2. A urine protein-to-creatinine ratio is 4560 mg/g. Other medical problems include hypertension, currently treated with furosemide 40 mg orally twice daily and lisinopril 40 mg once daily. Her BP is 160/85 mmHg.
KeywordsChronic Kidney Disease Correct Answer Autosomal Dominant Polycystic Kidney Disease Polycystic Kidney Disease Pediatric Nephrology
Unable to display preview. Download preview PDF.
- Hogg RJ, Portman RJ, Millimer D (2000) Evaluation of proteinuria and nephritic syndrome in children: Recommendations from a pediatric nephrology panel established at National Kidney Foundation conference on proteinuria, albuminuria, risk, detection, and elimination (PARDE). Pediatrics 105:1242–1249CrossRefPubMedGoogle Scholar
- National Kidney Foundation: K/DOQI clinical guidelines for chronic kidney disease: evaluation, classification, and stratification (2002). Am J Kidney Dis 29 (Suppl 1) S1–S266Google Scholar
- Levey AS, Greene T, Beck GJ, et al. (1999) Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? J Am Soc Nephrol 10:2436–2439Google Scholar
- Pedrini MT, Levey AS, Lau J, et al. (1996) The effect of dietary protein restriction on the progression of diabetic and non-diabetic renal disease: a meta-analysis. An Intern Med 124:267–637Google Scholar
- National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification (2002). Am J Kid Dis 39:S1–S266Google Scholar
- Dillon JJ (2001) Treating IgA nephropathy. J Am Soc Nephrol 2001; 12:846–847Google Scholar
- Ibanez L, Morlans M, Vidal X, et al. (2005) Case-control study of regular analgesic and nonsteroidal anti-inflammatory use and end-stage renalGoogle Scholar
- K/DOQI Clinical Practice Guidelines on Hypertension and antihypertensive agents in chronic kidney disease (2004). Am J Kidney Dis 43:(Suppl 1) S5–S10Google Scholar